158 | EPCORE DLBCL‐3: FIXED‐DURATION EPCORITAMAB MONOTHERAPY IN OLDER (≥ 75 Y), ANTHRACYCLINE‐INELIGIBLE PATIENTS WITH PREVIOUSLY UNTREATED LARGE B‐CELL LYMPHOMA (LBCL)

Documenti analoghi

• 281 | LONG‐TERM RESULTS FROM EPCORE NHL‐2: FIXED‐DURATION EPCORITAMAB + R‐CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA WITH HIGH‐RISK FEATURES
  di: L. Falchi, et al.
  Pubblicazione: (2025)
• 216 | EPCORITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND TRANSLATIONAL RESULTS FROM EPCORE CLL‐1
  di: B. Fakhri, et al.
  Pubblicazione: (2025)
• 282 | DURABLE EFFICACY WITH FIXED‐DURATION EPCORITAMAB + POLATUZUMAB, VEDOTIN, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA‐R‐CHP) FOR 1L DLBCL (EPCORE NHL‐5)
  di: D. Lavie, et al.
  Pubblicazione: (2025)
• 625 | OUTPATIENT ADMINISTRATION OF EPCORITAMAB MONOTHERAPY FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: UPDATE FROM EPCORE NHL‐6
  di: R. Vaidya, et al.
  Pubblicazione: (2025)
• 426 | EPCORITAMAB+GEMOX LEADS TO HIGH MRD‐NEGATIVITY RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: AN UPDATED LONGITUDINAL MRD ANALYSIS
  di: K. Karagoz, et al.
  Pubblicazione: (2025)